ATE421535T1 - Peg-modifiziertes erythropoietin - Google Patents
Peg-modifiziertes erythropoietinInfo
- Publication number
- ATE421535T1 ATE421535T1 AT01970285T AT01970285T ATE421535T1 AT E421535 T1 ATE421535 T1 AT E421535T1 AT 01970285 T AT01970285 T AT 01970285T AT 01970285 T AT01970285 T AT 01970285T AT E421535 T1 ATE421535 T1 AT E421535T1
- Authority
- AT
- Austria
- Prior art keywords
- peg
- epo
- conjugated
- native
- erythropoietin
- Prior art date
Links
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical class [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title abstract 8
- 229920001223 polyethylene glycol Polymers 0.000 abstract 6
- 102100031939 Erythropoietin Human genes 0.000 abstract 5
- 230000002459 sustained effect Effects 0.000 abstract 3
- 102000003951 Erythropoietin Human genes 0.000 abstract 2
- 108090000394 Erythropoietin Proteins 0.000 abstract 2
- 229940105423 erythropoietin Drugs 0.000 abstract 2
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
- 230000001766 physiological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000315421 | 2000-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE421535T1 true ATE421535T1 (de) | 2009-02-15 |
Family
ID=18794529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01970285T ATE421535T1 (de) | 2000-10-16 | 2001-09-28 | Peg-modifiziertes erythropoietin |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20040082765A1 (de) |
| EP (1) | EP1333036B1 (de) |
| JP (1) | JP5170931B2 (de) |
| AT (1) | ATE421535T1 (de) |
| AU (1) | AU2001290312A1 (de) |
| DE (1) | DE60137525D1 (de) |
| ES (1) | ES2320101T3 (de) |
| WO (1) | WO2002032957A1 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA008866B1 (ru) * | 2002-12-26 | 2007-08-31 | Маунтин Вью Фамэсьютикэлс, Инк. | ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ |
| US7655618B2 (en) | 2002-12-27 | 2010-02-02 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
| CA2509755A1 (en) | 2002-12-27 | 2004-07-22 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
| EP1471153A3 (de) * | 2003-03-21 | 2005-06-15 | F. Hoffmann-La Roche Ag | Transkriptionsaktivitätsassay |
| CA2458085A1 (en) | 2003-03-21 | 2004-09-21 | F. Hoffmann-La Roche Ag | Transcriptional activity assay |
| KR20060032140A (ko) * | 2003-05-30 | 2006-04-14 | 센토코 인코포레이티드 | 트랜스글루타미나아제를 이용한 신규 에리트로포이에틴접합체의 형성 |
| JP2007513965A (ja) * | 2003-12-10 | 2007-05-31 | ネクター セラピューティクス アラバマ，コーポレイション | ポリマー・活性剤複合体の二つの集団を含む組成物 |
| AU2004309083B2 (en) * | 2003-12-30 | 2010-11-11 | Augustinus Bader | Tissue regeneration method |
| EP1848461A2 (de) * | 2005-02-16 | 2007-10-31 | Nektar Therapeutics Al, Corporation | Konjugate einer epo-gruppierung und eines polymers |
| US20090042790A1 (en) * | 2005-06-13 | 2009-02-12 | Nastech Pharmaceutical Company Inc. | Transmucosal delivery of peptide derivatives |
| IL169377A (en) | 2005-06-23 | 2012-09-24 | Avigdor Shafferman | Uniformly conjugated serine hydrolases |
| WO2007026772A1 (ja) * | 2005-08-31 | 2007-03-08 | Kaneka Corporation | ネコ由来タンパク質のコード配列を含む外来性遺伝子を含むトランスジェニック鳥類およびその作製法 |
| US20080171696A1 (en) * | 2005-10-21 | 2008-07-17 | Avigenics, Inc. | Pharmacodynamically enhanced therapeutic proteins |
| CU23556A1 (es) * | 2005-11-30 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico |
| CA2647314A1 (en) | 2006-03-31 | 2007-11-08 | Baxter International Inc. | Pegylated factor viii |
| US7985839B2 (en) | 2006-03-31 | 2011-07-26 | Baxter International Inc. | Factor VIII polymer conjugates |
| US7982010B2 (en) | 2006-03-31 | 2011-07-19 | Baxter International Inc. | Factor VIII polymer conjugates |
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| WO2008012528A1 (en) | 2006-07-25 | 2008-01-31 | Lipoxen Technologies Limited | N-terminal polysialylation |
| GB0615067D0 (en) * | 2006-07-28 | 2006-09-06 | Ttp Communications Ltd | Reconfigurable signal processing scheme |
| PL2054074T3 (pl) * | 2006-08-04 | 2015-03-31 | Prolong Pharmaceuticals Llc | Zmodyfikowana erytropoetyna |
| CA2670618C (en) | 2006-12-15 | 2016-10-04 | Baxter International Inc. | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
| US8110651B2 (en) | 2008-01-11 | 2012-02-07 | Serina Therapeutics, Inc. | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same |
| US8101706B2 (en) | 2008-01-11 | 2012-01-24 | Serina Therapeutics, Inc. | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same |
| GB0922354D0 (en) | 2009-12-21 | 2010-02-03 | Polytherics Ltd | Novel polymer conjugates |
| ES2608457T3 (es) | 2009-05-20 | 2017-04-11 | Biomarin Pharmaceutical Inc. | Variantes de péptido natriurético de tipo C |
| KR101773918B1 (ko) * | 2009-09-15 | 2017-09-01 | 가부시키가이샤 가네카 | 수용성 장쇄 분자를 부가한 수식 에리스로포이에틴 |
| WO2015130963A2 (en) | 2014-02-27 | 2015-09-03 | Xenetic Biosciences, Inc. | Compositions and methods for administering insulin or insulin-like protein to the brain |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US5100664A (en) * | 1985-09-20 | 1992-03-31 | Cetus Corporation | Human IL-2 as a vaccine adjuvant |
| US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| JP2502646B2 (ja) | 1988-01-19 | 1996-05-29 | 松下電器産業株式会社 | バ―ナ |
| JPH029900A (ja) * | 1988-04-12 | 1990-01-12 | Kirin Amgen Inc | 修飾エリスロポエチン |
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| NZ250375A (en) * | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
| NO934477L (no) * | 1992-12-09 | 1994-06-10 | Ortho Pharma Corp | PEG hydrazon- og PEG oksim-bindingdannende reagenser og proteinderivater derav |
| GB9317618D0 (en) | 1993-08-24 | 1993-10-06 | Royal Free Hosp School Med | Polymer modifications |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5747446A (en) * | 1994-03-22 | 1998-05-05 | Beth Israel Deaconess Medical Center | Modified polypeptides with increased biological activity |
| US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| EP0816381B1 (de) * | 1995-03-10 | 2004-01-14 | NAKAMURA, Toshikazu | Menschlicher wachstumsfaktor (hgf), verändert durch polyethylenglykol |
| US5767078A (en) * | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
| EP1731174A3 (de) * | 1996-08-02 | 2007-01-17 | Ortho-McNeil Pharmaceutical, Inc. | Polypeptide mit durch Hydrazon oder Oxim Gruppe kovalent gebunden N-terminalen Polyethylen-glycol |
| DE69800640T2 (de) * | 1997-01-29 | 2001-07-05 | Polymasc Pharmaceuticals Plc, London | Pegylationsverfahren |
| ATE375363T1 (de) * | 1997-07-14 | 2007-10-15 | Bolder Biotechnology Inc | Derivate des wachstumshormons und verwandte proteine |
| WO2000032772A2 (en) * | 1998-11-30 | 2000-06-08 | Eli Lilly And Company | Erythropoietic compounds |
| BR122013003013B8 (pt) * | 1999-01-14 | 2021-07-06 | Bolder Biotechnology Inc | proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção |
| JP2002540065A (ja) | 1999-01-29 | 2002-11-26 | アムジェン インコーポレーテッド | Ｇｃｓｆコンジュゲート |
| JO2291B1 (en) * | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
| CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
-
2001
- 2001-09-28 US US10/399,254 patent/US20040082765A1/en not_active Abandoned
- 2001-09-28 DE DE60137525T patent/DE60137525D1/de not_active Expired - Lifetime
- 2001-09-28 JP JP2002536338A patent/JP5170931B2/ja not_active Expired - Lifetime
- 2001-09-28 EP EP01970285A patent/EP1333036B1/de not_active Expired - Lifetime
- 2001-09-28 ES ES01970285T patent/ES2320101T3/es not_active Expired - Lifetime
- 2001-09-28 WO PCT/JP2001/008539 patent/WO2002032957A1/ja not_active Ceased
- 2001-09-28 AT AT01970285T patent/ATE421535T1/de active
- 2001-09-28 AU AU2001290312A patent/AU2001290312A1/en not_active Abandoned
-
2006
- 2006-08-03 US US11/498,053 patent/US8022191B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20060276634A1 (en) | 2006-12-07 |
| EP1333036B1 (de) | 2009-01-21 |
| AU2001290312A1 (en) | 2002-04-29 |
| JP5170931B2 (ja) | 2013-03-27 |
| WO2002032957A1 (en) | 2002-04-25 |
| US8022191B2 (en) | 2011-09-20 |
| DE60137525D1 (de) | 2009-03-12 |
| ES2320101T3 (es) | 2009-05-19 |
| EP1333036A4 (de) | 2004-09-29 |
| EP1333036A1 (de) | 2003-08-06 |
| US20040082765A1 (en) | 2004-04-29 |
| JPWO2002032957A1 (ja) | 2004-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60137525D1 (de) | Peg-modifiziertes erythropoietin | |
| LU92175I2 (fr) | Lixisénatide | |
| ATE463260T1 (de) | Ortspezifische duale pegylation von proteine | |
| ATE364654T1 (de) | Polyamideketten von genauer länge und deren konjugate mit proteinen | |
| AU2001296962A1 (en) | Pegylated interleukin-10 | |
| ATE550041T1 (de) | Transglutaminase-vermittelte konjugation von peptiden | |
| PT1264840E (pt) | Péptidos de fusão inibidores, de acção prolongada, de infecção viral | |
| ES2308032T5 (es) | Derivados poliméricos de ácido maleámico y sus bioconjugados | |
| EA200100838A1 (ru) | Конъюгаты гксф | |
| FI921267A0 (fi) | Polyetylen-proteinkonjugater. | |
| DK0973819T3 (da) | Ikke-antigene forgrenede polymerkonjugater | |
| DK1274728T3 (da) | Fremgangsmåder og sammensætninger til forebyggelse og behandling af anæmi | |
| ATE505204T1 (de) | Konjugate von erythropoietin (epo) mit polyethylenglykol (peg) | |
| ATE312843T1 (de) | Neues cyclosporin mit verbesserter wirkung | |
| ATE88898T1 (de) | Cd4-polypeptidderivate. | |
| DE69432141D1 (de) | Taxane mit furyl-oder thienyl substituierten seitenketten | |
| DE60236796D1 (de) | Verzweigte polyalkylenglykole | |
| DK0557199T3 (da) | Polyethylenglycol-hirudin-konjugater, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af tromboser | |
| WO2005090395A3 (en) | Methods for increasing protein polyethylene glycol (peg) conjugation | |
| CA2373252A1 (en) | Long lasting anti-angiogenic peptides | |
| TR200200599T2 (tr) | İnsan insülini monomerik analogları. | |
| ATE313796T1 (de) | Konjugate definierter stöchiometrie | |
| WO2004043884A3 (en) | Novel acylating reagents | |
| CY1115962T1 (el) | Πεπτιδια που μειωνουν τα επιπεδα της γλυκοζης στο αιμα | |
| TH52654A (th) | แอนตี-แอนจิโอจินิก เปปไทด์ ที่มีอายุยาวนาน |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1333036 Country of ref document: EP |